Illustration: Gabriella Turrisi/Axios
Attovia Therapeutics, an immune-disease drug developer, raised $289 million, pricing its IPO at $17 per share—the top of its targeted range.
The big picture: The upsized deal underscores the continued appetite for biotech listings.
